TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16

Uzma A. Hasan, Elizabeth Bates, Fumihiko Takeshita, Alexandra Biliato, Rosita Accardi, Veronique Bouvard, Mariam Mansour, Isabelle Vincent, Lutz Gissmann, Thomas Iftner, Mario Sideri, Frank Stubenrauch, Massimo Tommasino

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Cervical cancer development is linked to the persistent infection by high-risk mucosal human papillomaviruses (HPVs) types. The E6 and E7 major oncoproteins from this dsDNA virus play a key role in the deregulation of ihe ceil cycle, apoptosis, and adaptive immune surveillance. In this study, we show for the first time that HPV type 16 (HPV16), the most carcinogenic type among the high-risk subgroup, interferes with innate immunity by affecting the expression of TLRs. Infection of human primary keratinocytes with HPV16 E6 and E7 recombinant retroviruses inhibits TLR9 transcription and hence functional loss of TLR9-regulated pathways. Similar findings were achieved in HPV16-positive cancer-derived cell lines and primary cervical cancers, demonstrating that this event occurs also in an in vivo context. Interestingly, E6 and E7 from the low-risk HPV type 6 are unable to down-regulate the TLR9 promoter. In addition, E6 and E7 from the high-risk HPV type 18, which are known to persist less competently in the host than HPV16, have reduced efficiency compared with HPV16 in inhibiting TLR9 transcription. Furthermore, a CpG motif derived from the HPV16 E6 DNA sequence activated TLR9, indicating this virus is able to initiate innate responses via the receptor it later down-regulates. This study reveals a novel mechanism used by HPV16 to suppress the host immune response by deregulating the TLR9 transcript, providing evidence that abolishing innate responses may be a crucial step involved in the carcinogenic events mediated by HPVs.

Original languageEnglish
Pages (from-to)3186-3197
Number of pages12
JournalJournal of Immunology
Volume178
Issue number5
Publication statusPublished - Mar 1 2007

Fingerprint

Human papillomavirus 16
Uterine Cervical Neoplasms
Down-Regulation
Human papillomavirus 6
Viruses
Human papillomavirus 18
Oncogene Proteins
Retroviridae
Infection
Keratinocytes
Innate Immunity
Apoptosis
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Immunology

Cite this

Hasan, U. A., Bates, E., Takeshita, F., Biliato, A., Accardi, R., Bouvard, V., ... Tommasino, M. (2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. Journal of Immunology, 178(5), 3186-3197.

TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. / Hasan, Uzma A.; Bates, Elizabeth; Takeshita, Fumihiko; Biliato, Alexandra; Accardi, Rosita; Bouvard, Veronique; Mansour, Mariam; Vincent, Isabelle; Gissmann, Lutz; Iftner, Thomas; Sideri, Mario; Stubenrauch, Frank; Tommasino, Massimo.

In: Journal of Immunology, Vol. 178, No. 5, 01.03.2007, p. 3186-3197.

Research output: Contribution to journalArticle

Hasan, UA, Bates, E, Takeshita, F, Biliato, A, Accardi, R, Bouvard, V, Mansour, M, Vincent, I, Gissmann, L, Iftner, T, Sideri, M, Stubenrauch, F & Tommasino, M 2007, 'TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16', Journal of Immunology, vol. 178, no. 5, pp. 3186-3197.
Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. Journal of Immunology. 2007 Mar 1;178(5):3186-3197.
Hasan, Uzma A. ; Bates, Elizabeth ; Takeshita, Fumihiko ; Biliato, Alexandra ; Accardi, Rosita ; Bouvard, Veronique ; Mansour, Mariam ; Vincent, Isabelle ; Gissmann, Lutz ; Iftner, Thomas ; Sideri, Mario ; Stubenrauch, Frank ; Tommasino, Massimo. / TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. In: Journal of Immunology. 2007 ; Vol. 178, No. 5. pp. 3186-3197.
@article{41e427c9ea75482cae56434e2b7fd41d,
title = "TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16",
abstract = "Cervical cancer development is linked to the persistent infection by high-risk mucosal human papillomaviruses (HPVs) types. The E6 and E7 major oncoproteins from this dsDNA virus play a key role in the deregulation of ihe ceil cycle, apoptosis, and adaptive immune surveillance. In this study, we show for the first time that HPV type 16 (HPV16), the most carcinogenic type among the high-risk subgroup, interferes with innate immunity by affecting the expression of TLRs. Infection of human primary keratinocytes with HPV16 E6 and E7 recombinant retroviruses inhibits TLR9 transcription and hence functional loss of TLR9-regulated pathways. Similar findings were achieved in HPV16-positive cancer-derived cell lines and primary cervical cancers, demonstrating that this event occurs also in an in vivo context. Interestingly, E6 and E7 from the low-risk HPV type 6 are unable to down-regulate the TLR9 promoter. In addition, E6 and E7 from the high-risk HPV type 18, which are known to persist less competently in the host than HPV16, have reduced efficiency compared with HPV16 in inhibiting TLR9 transcription. Furthermore, a CpG motif derived from the HPV16 E6 DNA sequence activated TLR9, indicating this virus is able to initiate innate responses via the receptor it later down-regulates. This study reveals a novel mechanism used by HPV16 to suppress the host immune response by deregulating the TLR9 transcript, providing evidence that abolishing innate responses may be a crucial step involved in the carcinogenic events mediated by HPVs.",
author = "Hasan, {Uzma A.} and Elizabeth Bates and Fumihiko Takeshita and Alexandra Biliato and Rosita Accardi and Veronique Bouvard and Mariam Mansour and Isabelle Vincent and Lutz Gissmann and Thomas Iftner and Mario Sideri and Frank Stubenrauch and Massimo Tommasino",
year = "2007",
month = "3",
day = "1",
language = "English",
volume = "178",
pages = "3186--3197",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16

AU - Hasan, Uzma A.

AU - Bates, Elizabeth

AU - Takeshita, Fumihiko

AU - Biliato, Alexandra

AU - Accardi, Rosita

AU - Bouvard, Veronique

AU - Mansour, Mariam

AU - Vincent, Isabelle

AU - Gissmann, Lutz

AU - Iftner, Thomas

AU - Sideri, Mario

AU - Stubenrauch, Frank

AU - Tommasino, Massimo

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Cervical cancer development is linked to the persistent infection by high-risk mucosal human papillomaviruses (HPVs) types. The E6 and E7 major oncoproteins from this dsDNA virus play a key role in the deregulation of ihe ceil cycle, apoptosis, and adaptive immune surveillance. In this study, we show for the first time that HPV type 16 (HPV16), the most carcinogenic type among the high-risk subgroup, interferes with innate immunity by affecting the expression of TLRs. Infection of human primary keratinocytes with HPV16 E6 and E7 recombinant retroviruses inhibits TLR9 transcription and hence functional loss of TLR9-regulated pathways. Similar findings were achieved in HPV16-positive cancer-derived cell lines and primary cervical cancers, demonstrating that this event occurs also in an in vivo context. Interestingly, E6 and E7 from the low-risk HPV type 6 are unable to down-regulate the TLR9 promoter. In addition, E6 and E7 from the high-risk HPV type 18, which are known to persist less competently in the host than HPV16, have reduced efficiency compared with HPV16 in inhibiting TLR9 transcription. Furthermore, a CpG motif derived from the HPV16 E6 DNA sequence activated TLR9, indicating this virus is able to initiate innate responses via the receptor it later down-regulates. This study reveals a novel mechanism used by HPV16 to suppress the host immune response by deregulating the TLR9 transcript, providing evidence that abolishing innate responses may be a crucial step involved in the carcinogenic events mediated by HPVs.

AB - Cervical cancer development is linked to the persistent infection by high-risk mucosal human papillomaviruses (HPVs) types. The E6 and E7 major oncoproteins from this dsDNA virus play a key role in the deregulation of ihe ceil cycle, apoptosis, and adaptive immune surveillance. In this study, we show for the first time that HPV type 16 (HPV16), the most carcinogenic type among the high-risk subgroup, interferes with innate immunity by affecting the expression of TLRs. Infection of human primary keratinocytes with HPV16 E6 and E7 recombinant retroviruses inhibits TLR9 transcription and hence functional loss of TLR9-regulated pathways. Similar findings were achieved in HPV16-positive cancer-derived cell lines and primary cervical cancers, demonstrating that this event occurs also in an in vivo context. Interestingly, E6 and E7 from the low-risk HPV type 6 are unable to down-regulate the TLR9 promoter. In addition, E6 and E7 from the high-risk HPV type 18, which are known to persist less competently in the host than HPV16, have reduced efficiency compared with HPV16 in inhibiting TLR9 transcription. Furthermore, a CpG motif derived from the HPV16 E6 DNA sequence activated TLR9, indicating this virus is able to initiate innate responses via the receptor it later down-regulates. This study reveals a novel mechanism used by HPV16 to suppress the host immune response by deregulating the TLR9 transcript, providing evidence that abolishing innate responses may be a crucial step involved in the carcinogenic events mediated by HPVs.

UR - http://www.scopus.com/inward/record.url?scp=33847379522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847379522&partnerID=8YFLogxK

M3 - Article

C2 - 17312167

AN - SCOPUS:33847379522

VL - 178

SP - 3186

EP - 3197

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -